NYSE:DHR

Danaher - DHR Stock Forecast, Price & News

$259.02

-2.14 (-0.82%)

(As of 11/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $256.65
▼
$261.67
50-Day Range: $241.42
▼
$282.29
52-Week Range: $233.71
▼
$331.68

Volume: 2.13 million shs
Average Volume: 2.47 million shs
Market Capitalization: $188.56 billion

P/E Ratio: 28.62
Dividend Yield: 0.38%
Price Target: $312.50

Danaher MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 19.7% Upside
$310.17 Price Target
Short Interest: Healthy
0.55% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -1.31
Upright™ Environmental Score
News Sentiment: 0.39
Based on 9 Articles This Week
Insider Trading: Selling Shares
$10.55 M Sold Last Quarter
Proj. Earnings Growth: -1.42%
From $10.53 to $10.38 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Multi-Sector Conglomerates Sector

4th out of 18 stocks

Process Control Instruments Industry

3rd out of 11 stocks

3.4

Analyst's Opinion

Consensus Rating
Danaher has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $310.17, Danaher has a forecasted upside of 19.7% from its current price of $259.02.
Amount of Analyst Coverage
Danaher has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.55% of the float of Danaher has been sold short.
Short Interest Ratio / Days to Cover
Danaher has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Danaher has recently decreased by 7.67%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Yield
Danaher has a dividend yield of 0.38%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Danaher has been increasing its dividend for 6 years.
Dividend Coverage
The dividend payout ratio of Danaher is 11.05%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Danaher will have a dividend payout ratio of 9.63% next year. This indicates that Danaher will be able to sustain or increase its dividend.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Danaher has received a 46.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Prenatal screening services", "Clinical research services", "Point-of-care tests", "Non-invasive prenatal testing services", "Private genetic testing services", and "AI powered medical diagnostic machines" products. See details.
Environmental Sustainability
The Environmental Impact score for Danaher is -1.31.

1.3

News and Social Media Coverage

News Sentiment
Danaher has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Multi-Sector Conglomerates companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Danaher this week, compared to 9 articles on an average week.
Search Interest
Only 26 people have searched for DHR on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
Only 18 people have added Danaher to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Danaher insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,550,749.00 in company stock.
Percentage Held by Insiders
11.20% of the stock of Danaher is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
77.27% of the stock of Danaher is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Danaher are expected to decrease by -1.42% in the coming year, from $10.53 to $10.38 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Danaher is 28.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.14.
Price to Earnings Ratio vs. Sector
The P/E ratio of Danaher is 28.62, which means that it is trading at a more expensive P/E ratio than the Multi-Sector Conglomerates sector average P/E ratio of about 4.99.
Price to Earnings Growth Ratio
Danaher has a PEG Ratio of 2.07. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Danaher has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Danaher (NYSE:DHR) Stock

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Stock News Headlines

November 30, 2022 | americanbankingnews.com

Danaher Co. (NYSE:DHR) EVP Joakim Weidemanis Sells 9,508 Shares

November 28, 2022 | finance.yahoo.com

A Look At The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

November 24, 2022 | finance.yahoo.com

Declining Stock and Solid Fundamentals: Is The Market Wrong About Danaher Corporation (NYSE:DHR)?

November 23, 2022 | stocknews.com

2 Deeply Discounted Stocks to Buy Now

November 20, 2022 | finance.yahoo.com

Danaher's (NYSE:DHR) earnings growth rate lags the 23% CAGR delivered to shareholders

November 16, 2022 | finance.yahoo.com

Here's Why Danaher (NYSE:DHR) Has Caught The Eye Of Investors

November 15, 2022 | finance.yahoo.com

Cepheid Launches Multiplex Vaginal Panel (MVP) to Support More Accurate Women's Health Diagnosis in U.S.

November 14, 2022 | finance.yahoo.com

Danaher (DHR) Just Reclaimed the 200-Day Moving Average

November 14, 2022 | finance.yahoo.com

Here's How Much a $1000 Investment in Danaher Made 10 Years Ago Would Be Worth Today

November 12, 2022 | finance.yahoo.com

Danaher's (NYSE:DHR) 24% CAGR outpaced the company's earnings growth over the same five-year period

November 10, 2022 | finance.yahoo.com

Danaher Launches Beacon Initiative and Its First Partnership Focused on Gene Therapy Innovation

November 8, 2022 | finance.yahoo.com

Possible bearish signals as Danaher Corporation (NYSE:DHR) insiders disposed of US$11m worth of stock

November 4, 2022 | finance.yahoo.com

Those who invested in Danaher (NYSE:DHR) five years ago are up 166%

November 1, 2022 | finance.yahoo.com

Danaher Is Still Searching for a Bottom on the Charts

November 1, 2022 | finance.yahoo.com

Cepheid, which made early Covid test, now cutting 1,000 Bay Area jobs

October 27, 2022 | finance.yahoo.com

Is Weakness In Danaher Corporation (NYSE:DHR) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

October 26, 2022 | msn.com

Analyzing Danaher's Short Interest

October 25, 2022 | seekingalpha.com

Danaher Stock Has Serious Boom/Bust Risk

October 25, 2022 | cnbc.com

What Cramer is watching Monday — Fed pivot, Xi consolidates, DHR and META downgrades

October 25, 2022 | msn.com

Where Danaher Stands With Analysts

October 25, 2022 | markets.businessinsider.com

What 9 Analyst Ratings Have To Say About Danaher

October 20, 2022 | benzinga.com

Tissue Diagnostics Global Market Report 2022: Featuring Roche, Danaher, Thermo Fisher Scientific, Abbott, - Benzinga

October 20, 2022 | in.investing.com

Danaher earnings, Revenue beat in Q3 - Investing.com India

October 20, 2022 | seekingalpha.com

Danaher posts Q3 beat after broad-based growth (NYSE:DHR) - Seeking Alpha

October 20, 2022 | finance.yahoo.com

Danaher Reports Third Quarter 2022 Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Company Calendar

Ex-Dividend for 10/28 Dividend: 9/29/2022
Last Earnings: 10/20/2022
Dividend Payable: 10/28/2022
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 1/26/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Process control instruments
Sub-Industry: Industrial Conglomerates
Sector: Multi-Sector Conglomerates
Current Symbol: NYSE:DHR
CUSIP: 23585110
CIK: 313616
Web: www.danaher.com
Phone: (202) 828-0850
Fax: 202-828-0860
Employees: 80,000
Year Founded: 1984

Price Target and Rating

Average Stock Price Forecast: $310.17
High Stock Price Forecast: $340.00
Low Stock Price Forecast: $265.00
Forecasted Upside/Downside: +20.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): $9.05
Trailing P/E Ratio: 28.62
Forward P/E Ratio: 24.60
P/E Growth: 2.07
Net Income: $6.43 billion
Net Margins: 21.65%
Pretax Margin: 26.19%
Return on Equity: 18.33%
Return on Assets: 9.75%

Debt

Debt-to-Equity Ratio: 0.41
Current Ratio: 1.78
Quick Ratio: 1.38

Sales & Book Value

Annual Sales: $29.45 billion
Price / Sales: 6.40
Cash Flow: $13.48 per share
Price / Cash Flow: 19.21
Book Value: $62.26 per share
Price / Book: 4.16

Miscellaneous

Outstanding Shares: 727,960,000
Free Float: 646,431,000
Market Cap: $188.56 billion
Optionable: Optionable
Beta: 0.82

Social Links

Key Executives

Mr. Steven M. Rales (Age 71)
Co-Founder & Chairman

Mr. Rainer M. Blair (Age 58)
Pres, CEO & Director
Comp: $5.77M

Mr. Mitchell P. Rales (Age 65)
Co-Founder & Director

Mr. Matthew R. McGrew (Age 50)
CFO & Exec. VP
Comp: $2.68M

Ms. Angela S. Lalor (Age 57)
Part Time Advisor
Comp: $3.23M

Mr. Joakim Weidemanis (Age 53)
Exec. VP
Comp: $3.06M

Ms. Jennifer L. Honeycutt (Age 52)
Exec. VP
Comp: $2.44M

Mr. Christopher M. Bouda
Chief Accounting Officer

Dr. Jose-Carlos Gutierrez-Ramos Ph.D. (Age 58)
Sr. VP & Chief Science Officer

Mr. John Bedford
VP of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DHR Stock - Frequently Asked Questions

Should I buy or sell Danaher stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DHR shares.
View DHR analyst ratings or view top-rated stocks.
What is Danaher's stock price forecast for 2023?: 12 analysts have issued twelve-month price objectives for Danaher's shares. Their DHR share price forecasts range from $265.00 to $340.00. On average, they predict the company's stock price to reach $310.17 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price.
View analysts price targets for DHR or view top-rated stocks among Wall Street analysts.
How have DHR shares performed in 2022?: Danaher's stock was trading at $329.01 at the beginning of the year. Since then, DHR stock has decreased by 21.3% and is now trading at $259.02.
View the best growth stocks for 2022 here.
Are investors shorting Danaher?: Danaher saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,610,000 shares, a decline of 7.7% from the October 31st total of 3,910,000 shares. Based on an average trading volume of 2,710,000 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.6% of the shares of the company are sold short.
View Danaher's Short Interest.
When is Danaher's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, January 26th 2023.
View our DHR earnings forecast.
How were Danaher's earnings last quarter?: Danaher Co. (NYSE:DHR) posted its quarterly earnings data on Thursday, October, 20th. The conglomerate reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.32. The conglomerate had revenue of $7.66 billion for the quarter, compared to analyst estimates of $7.17 billion. Danaher had a trailing twelve-month return on equity of 18.33% and a net margin of 21.65%. The firm's revenue was up 6.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.39 earnings per share.
Read the conference call transcript.
How often does Danaher pay dividends? What is the dividend yield for Danaher?: Danaher declared a quarterly dividend on Tuesday, September 13th. Investors of record on Friday, September 30th will be paid a dividend of $0.25 per share on Friday, October 28th. This represents a $1.00 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date is Thursday, September 29th.
Read our dividend analysis for DHR.
Is Danaher a good dividend stock?: Danaher (NYSE:DHR) pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.38%. The company has been increasing its dividend for 6 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 11.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DHR will have a dividend payout ratio of 9.63% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DHR.

What is Rainer M. Blair's approval rating as Danaher's CEO?: 27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Danaher own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC), Alibaba Group (BABA), Mastercard (MA), PayPal (PYPL) and AbbVie (ABBV).
What is Danaher's stock symbol?: Danaher trades on the New York Stock Exchange (NYSE) under the ticker symbol "DHR."
Who are Danaher's major shareholders?: Danaher's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.38%), Bank of New York Mellon Corp (0.97%), Edgewood Management LLC (0.96%), Nuveen Asset Management LLC (0.57%), Fisher Asset Management LLC (0.54%) and Pictet Asset Management SA (0.48%). Insiders that own company stock include Alan G Spoon, Angela S Lalor, Angela S Lalor, Brian W Ellis, Daniel L Comas, Daniel Raskas, Donald J Ehrlich, Elias A Zerhouni, Georgeann Couchara, Jennifer Honeycutt, Joakim Weidemanis, John T Schwieters, Linda P Hefner, Matthew Mcgrew, Mitchell P Rales, Rainer Blair, Robert S Lutz, Teri List, Thomas Patrick Joyce Jr, Walter G Lohr, William K Daniel and William King.
View institutional ownership trends.
How do I buy shares of Danaher?: Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Danaher's stock price today?: One share of DHR stock can currently be purchased for approximately $259.02.
How much money does Danaher make?: Danaher (NYSE:DHR) has a market capitalization of $188.56 billion and generates $29.45 billion in revenue each year. The conglomerate earns $6.43 billion in net income (profit) each year or $9.05 on an earnings per share basis.
How many employees does Danaher have?: The company employs 80,000 workers across the globe.
Does Danaher have any subsidiaries?: The following companies are subsidiares of Danaher: AB SCIEX, AB Sciex LLC, AB Sciex LP, AB Sciex Pte Ltd., Accu-Sort Systems, Acme Cleveland Corporation, Advanced Vision Technology, Aldevron, Aldevron L.L.C., American Precision Industries, Applied Biosystems, Applitek NV, Aquatic Infomatics ULC, Aquatic Informatics, Armstrong Tools, BC Distribution BV, Beckman Coulter, Beckman Coulter Australia Pty Ltd, Beckman Coulter Biotechnology Suzhou Co. Ltd., Beckman Coulter Canada LP, Beckman Coulter Commercial Enterprise China Co. Ltd., Beckman Coulter France S.A.S., Beckman Coulter G.m.b.H., Beckman Coulter Genomics Inc., Beckman Coulter Hong Kong Limited, Beckman Coulter Inc., Beckman Coulter India Private Limited, Beckman Coulter International SA, Beckman Coulter International Shanghai Trading Co., Beckman Coulter Ireland Inc., Beckman Coulter K.K., Beckman Coulter Korea Ltd, Beckman Coulter Laboratory Systems Suzhou Co. Ltd., Beckman Coulter Limited Liability Company, Beckman Coulter Nederland B.V., Beckman Coulter Nippon GK, Beckman Coulter S.L.U., Beckman Coulter Saudi Arabia Co.Ltd., Beckman Coulter Srl, Beckman Coulter Taiwan Inc., Beckman Coulter United Kingdom Limited, Beckman Coulter de Mexico S.A. de C.V., Beckman Finance ApS, Biacore International AB, Biosafe S.A., Blue Software LLC, Cepheid, Cepheid AB, Cepheid Canada ULC, Cepheid Europe SAS, Cepheid GmbH, Cepheid HBDC SAS, Cepheid India Private Limited, Cepheid UK Ltd., ChemTreat, ChemTreat Inc., Cispus Hong Kong Holding Limited, Cytiva, Cytiva BioProcess R&D AB, Cytiva Biotechnology Guangzhou Co. Ltd., Cytiva Biotechnology Hang Zhou Co. Ltd., Cytiva Europe GmbH, Cytiva Sweden AB, DCHL Holding BV, DH Denmark Holding ApS, DH Europe Finance II Sarl, DH Europe Finance Sarl, DH Holding Italia SRL, DH Holdings Germany LLC, DH II Luxembourg Sarl, DH Japan Finance Sarl, DH Switzerland Finance Sarl, DH Technologies Development Pte Ltd., DHCY Limited, DHKAB Company AB, DTIL Ireland Holdings Ltd., Danaher China Holdings Ltd., Danaher Finance Company AB, Danaher HK Holdings Ltd., Danaher Medical ApS, Danaher Shanghai Management Co. Ltd., Delta Consolidated Industries, Devicore Medical Products Inc., Easco Hand Tools, Esko, Esko BV, Esko Graphics BV, Esko Graphics Inc., Esko Software BV, Fluke, GE Biopharma, Gelman Sciences Inc., Gendex, Genetix Group, Gilbarco Veeder Root, Gilzoni Ltd., Global Life Sciences Solutions Austria GmbH & Co. KG, Global Life Sciences Solutions Germany GmbH, Global Life Sciences Solutions Korea Ltd., Global Life Sciences Solutions Manufacturing UK Ltd, Global Life Sciences Solutions Operations UK Ltd, Global Life Sciences Solutions Singapore Pte Ltd, Global Life Sciences Solutions USA LLC, Global Life Sciences Technologies Japan KK, Global Life Sciences Technologies Shanghai Co Ltd., Hach Company, Hach Lange GmbH, Hach Lange Sàrl, Hach Water Quality Analytical Instru. Shanghai Co. Ltd., HemoCue AB, HyClone Laboratories LLC, Hybritech Incorporated, Hyclone Life Sciences Solutions India Private Limited, ID Business Solutions Limited, IDBS Group, IRIS International, Imaging Sciences International, Immunotech Sro, Intabio LLC, Integrated DNA Technologies, Integrated DNA Technologies BVBA, Integrated DNA Technologies Inc., Integrated DNA Technologies Pte. Ltd., Intermountain Life Sciences LLC, Iris International Inc., KaVo, KaVo Kerr, Kaltenbach & Voigt, Keithley Instruments, Kipp & Zonen BV, Kollmorgen, Labcyte Inc., Laetus, Launchchange Holding Company, Leica Biosystems Imaging Inc., Leica Biosystems Melbourne Pty Ltd, Leica Biosystems Newcastle Limited, Leica Biosystems Nussloch GmbH, Leica Biosystems Richmond Inc., Leica Instruments Singapore Pte Limited, Leica Microsystems, Leica Microsystems CMS GmbH, Leica Microsystems Cambridge Limited, Leica Microsystems IR GmbH, Leica Microsystems Inc., Leica Microsystems Limited, Leica Microsystems UK Limited, Leica Mikrosysteme GmbH, Leica Mikrosysteme Vertrieb GmbH, Life Sciences Holdings France SAS, Life Sciences IP Holdings Corporation, Lifschultz Industries, Linx Printing Technologies, Linx Printing Technologies Limited, MDS Analytical Technologies, Marconi Data Systems, Microtest, Molecular Devices, Molecular Devices LLC, Navman Wireless, Navman Wireless OEM Solutions, Nihon Pall Ltd., Nobel Biocare, OTT Hydromet Corp, Pall Aeropower Corporation, Pall Artelis BVBA, Pall Asia Holdings Inc., Pall Austar Lifesciences Limited, Pall Australia Pty. Ltd., Pall Austria Filter Ges.m.b.h, Pall Canada ULC, Pall China Co. Ltd., Pall Corporation, Pall Europe Limited, Pall Filtersystems GmbH, Pall Filtration Pte. Ltd., Pall Filtration and Separations Group Inc., Pall France SAS, Pall GmbH, Pall India Pvt. Ltd., Pall International Sarl, Pall Italia Srl, Pall Korea Ltd., Pall Life Sciences Belgium BV, Pall Life Sciences Puerto Rico LLC, Pall Manufacturing UK Limited, Pall Medistad BV, Pall Netherlands BV Irish Branch, Pall Schweiz GmbH, Pall Technology UK Limited, PaloDEX, Pantone LLC, Pelton & Crane, Phenomenex, Phenomenex Inc., Precision NanoSystems, Precision Nanosystems ULC, Radiometer, Radiometer Medical ApS, Radiometer Turku Oy, Raytek, Reytek Corporation, Sea-Bird Electronics Inc., Sedaru Inc., Shanghai AB Sciex Analytical Instrument Trading Co. Ltd., Skyland Analytics Inc., Sutron, Swift Biosciences Inc., Sybron Dental Specialties, Tektronix, Thomson Industries, Trojan Technologies, Trojan Technologies Group ULC, VSS Monitoring, Vanrx Pharmasystems Inc., Videojet Do Brasil Comércio de Equipamentos Para Codificação Industrial Ltda., Videojet Technologies Europe B.V., Videojet Technologies GmbH, Videojet Technologies Inc., Videojet Technologies S Pte.Ltd., Viridor Waste Management Limited, Vision Systems Limited, Willett International, X-Ray Optical Systems Inc., X-Rite, X-Rite Europe GmbH, X-Rite Incorporated, XOS, Yukon Hong Kong Holding Limited, and Zhuhai S.E.Z. Videojet Electronics Ltd..
Read More
How can I contact Danaher?: Danaher's mailing address is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. The official website for the company is www.danaher.com. The conglomerate can be reached via phone at (202) 828-0850, via email at investor.relations@danaher.com, or via fax at 202-828-0860.

This page (NYSE:DHR) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial